The European Partnership for Alternative Approaches to Animal Testing (EPAA) supports students and young scientists with outstanding work in the field of alternative approaches for attending a high-profile scientific event. The deadline for participation in MPS World summit as well as for the SETAC congress is 14 February 2025.
A group of Republican and Democratic senators has reintroduced a bill urging the Food and Drug Administration (FDA) to adopt modern alternatives to animal testing.
At the end of January, an ESAC statement was published following an evaluation of the in vitro test methods “Reconstructed human Skin (RS) Comet” and “Micronucleus (RSMN)” for the assessment of genotoxicity. The assessments appear promising.
The Volkswagen Foundation is funding the development of the service platform “Primary Tissue Pipeline” for two years. The service platform facilitates access to primary human tissue for researchers at Charité/BIH, thus improving research opportunities at Charité.
A study published in Nature suggests that lab-grown organoids can help predict the treatment effects of genetic drugs made from RNA for people with rare diseases.
Researchers at the University of Basel used the method of high-throughput metabolomics to simultaneously test the effects of more than 1,500 active substances on the metabolism of cells.
The Foundation for the Promotion of Research into Alternative and Complementary Methods to Animal Experiments (Stiftung zur Förderung der Erforschung von Ersatz- und Ergänzungsmethoden zum Tierversuch, set Foundation for short) is suspending its funding round this year.
Using a brain organoid model, a research team from the Department of Biomedical Engineering at Tufts University in Medford, Massachusetts, in collaboration with the University of Oxford, has observed that neuronal injury can reactivate latent herpes type 1 viruses, leading to the production and accumulation of ß-amyloid and phosphorylated tauproein, which promotes synaptic dysfunction and neurodegeneration.
A research team led by Prof. James Hickman of Hesperos Inc., in collaboration with the University of Central Florida in Orlando, has developed a novel multi-organ MPS model to investigate the efficacy and off-target toxicity of naloxone in combination with opioids.
The US Food and Drug Administration (FDA) has published a draft guidance document on the use of artificial intelligence for the safety assessment of drugs and biological products.